Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genmab, Lilly Enter DuoBody Platform Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Genmab, Lilly Enter DuoBody Platform Pact

To explore Genmab’s DuoBody for creation of antibodies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Genmab has entered a research collaboration with Eli Lilly and Co. for the use Genmab’s DuoBody technology platform to create bispecific antibodies. Lilly will initially evaluate the DuoBody technology platform in house. Financial terms were not disclosed. 
 
Jan van de Winkel, Ph.D., chief executive officer of Genmab, commented, “Our DuoBody platform continues to attract strong interest from the pharmaceutical industry and we are pleased to enter our fifth partnership for this innovative bispecific antibody technology. Under this new collaboration, Lilly will evaluate the capabilities and strengths of our DuoBody platform and may consider entering a commercial license agreement if the evaluation is successful.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics